CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future?
Abstract Chimeric antigen receptor (CAR) T-cell therapy targeting B cells has shown promising results, including drug-free remission, in adult-onset autoimmune diseases. Extending this therapeutic approach to the pediatric population, particularly for juvenile autoimmune diseases, presents an exciti...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Arthritis Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13075-025-03564-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849729153804271616 |
|---|---|
| author | Maurine Jouret Sebastien Viel Benjamin Fournier Sarah Benezech Jérome Avouac Marc Scherlinger Alexandre Belot for the C3I consortium |
| author_facet | Maurine Jouret Sebastien Viel Benjamin Fournier Sarah Benezech Jérome Avouac Marc Scherlinger Alexandre Belot for the C3I consortium |
| author_sort | Maurine Jouret |
| collection | DOAJ |
| description | Abstract Chimeric antigen receptor (CAR) T-cell therapy targeting B cells has shown promising results, including drug-free remission, in adult-onset autoimmune diseases. Extending this therapeutic approach to the pediatric population, particularly for juvenile autoimmune diseases, presents an exciting opportunity. However, challenges specific to juvenile-onset autoimmune conditions, such as long-term adverse events, heightened disease activity, and the imperative to reduce steroid exposure, must be considered. While this strategy appears viable for these severe conditions, the limited data available for this population and the absence of evidence on cases with a high genetic component, such as monogenic lupus, represent significant challenges. Most monogenic lupus cases are associated with innate immune defects, and the involvement of B cells in these genetic anomalies remains poorly understood. In this review, we examine the potential indications, current knowledge, and limitations of CAR-T cell therapy in juvenile-onset autoimmune diseases, extending the discussion beyond early-onset lupus. |
| format | Article |
| id | doaj-art-11fce15db94b4dd79a145ef740bf762a |
| institution | DOAJ |
| issn | 1478-6362 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Arthritis Research & Therapy |
| spelling | doaj-art-11fce15db94b4dd79a145ef740bf762a2025-08-20T03:09:19ZengBMCArthritis Research & Therapy1478-63622025-05-0127111410.1186/s13075-025-03564-1CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future?Maurine Jouret0Sebastien Viel1Benjamin Fournier2Sarah Benezech3Jérome Avouac4Marc Scherlinger5Alexandre Belot6for the C3I consortiumNational Referee Centre for Pediatric-Onset Rheumatic and Autoimmune Diseases (RAISE), Pediatric Nephrology, Rheumatology, Dermatology Unit, HFME, Hospices Civils de LyonInternational Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBLDepartment for Immunology, Hematology and Pediatric Rheumatology, Necker Hospital, APHP, Institut IMAGINEInternational Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBLRheumatology Department, Cochin Hospital, AP-HP. Centre Université Paris-CitéRheumatology Department, Strasbourg University HospitalNational Referee Centre for Pediatric-Onset Rheumatic and Autoimmune Diseases (RAISE), Pediatric Nephrology, Rheumatology, Dermatology Unit, HFME, Hospices Civils de LyonAbstract Chimeric antigen receptor (CAR) T-cell therapy targeting B cells has shown promising results, including drug-free remission, in adult-onset autoimmune diseases. Extending this therapeutic approach to the pediatric population, particularly for juvenile autoimmune diseases, presents an exciting opportunity. However, challenges specific to juvenile-onset autoimmune conditions, such as long-term adverse events, heightened disease activity, and the imperative to reduce steroid exposure, must be considered. While this strategy appears viable for these severe conditions, the limited data available for this population and the absence of evidence on cases with a high genetic component, such as monogenic lupus, represent significant challenges. Most monogenic lupus cases are associated with innate immune defects, and the involvement of B cells in these genetic anomalies remains poorly understood. In this review, we examine the potential indications, current knowledge, and limitations of CAR-T cell therapy in juvenile-onset autoimmune diseases, extending the discussion beyond early-onset lupus.https://doi.org/10.1186/s13075-025-03564-1LupusJuvenile dermatomyositisMonogenic lupusCAR-T cellsCD19B cells |
| spellingShingle | Maurine Jouret Sebastien Viel Benjamin Fournier Sarah Benezech Jérome Avouac Marc Scherlinger Alexandre Belot for the C3I consortium CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future? Arthritis Research & Therapy Lupus Juvenile dermatomyositis Monogenic lupus CAR-T cells CD19 B cells |
| title | CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future? |
| title_full | CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future? |
| title_fullStr | CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future? |
| title_full_unstemmed | CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future? |
| title_short | CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future? |
| title_sort | car t cell therapy for juvenile onset autoimmune diseases a promising future |
| topic | Lupus Juvenile dermatomyositis Monogenic lupus CAR-T cells CD19 B cells |
| url | https://doi.org/10.1186/s13075-025-03564-1 |
| work_keys_str_mv | AT maurinejouret cartcelltherapyforjuvenileonsetautoimmunediseasesapromisingfuture AT sebastienviel cartcelltherapyforjuvenileonsetautoimmunediseasesapromisingfuture AT benjaminfournier cartcelltherapyforjuvenileonsetautoimmunediseasesapromisingfuture AT sarahbenezech cartcelltherapyforjuvenileonsetautoimmunediseasesapromisingfuture AT jeromeavouac cartcelltherapyforjuvenileonsetautoimmunediseasesapromisingfuture AT marcscherlinger cartcelltherapyforjuvenileonsetautoimmunediseasesapromisingfuture AT alexandrebelot cartcelltherapyforjuvenileonsetautoimmunediseasesapromisingfuture AT forthec3iconsortium cartcelltherapyforjuvenileonsetautoimmunediseasesapromisingfuture |